Основная статистика
| CIK | 1716166 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Vivos Therapeutics, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| September 5, 2025 |
As filed with the Securities and Exchange Commission on September 5, 2025 As filed with the Securities and Exchange Commission on September 5, 2025 Registration No. |
|
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2025 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commission |
|
| August 25, 2025 |
Exhibit 99.1 R.D. PRABHU, LATA K. SHETE, M.D.s FINANCIAL STATEMENTS DECEMBER 31, 2024 and 2023 R.D. PRABHU, LATA K. SHETE, M.D. DECEMBER 31, 2024 and 2023 TABLE OF CONTENTS PAGE NO. INDEPENDENT AUDITORS’ REPORT 1 - 2 FINANCIAL STATEMENTS Balance Sheets 3 Statements of Income and Changes in Equity 4 - 5 Statements of Cash Flows 6 Notes to Financial Statements 7- 14 Report of Independent Auditors Th |
|
| August 25, 2025 |
Exhibit 99.2 R.D. PRABHU, LATA K. SHETE, M.D.s UNAUDITED FINANCIAL STATEMENTS As of March 31, 2025 and December 31, 2024 and for the Three Months Ended March 31, 2025 and 2024 TABLE OF CONTENTS PAGE NO. FINANCIAL STATEMENTS Balance Sheets as of March 31, 2025 and December 31, 2024 1 Statements of Operations for the three months ended March 31, 2025 and 2024 2 Statements of Stockholder’s Equity as |
|
| August 25, 2025 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Summary of Transaction On June 10, 2025 (the “Closing Date”), Vivos Pharmaceuticals, Inc. (“Vivos” or the “Company”) closed its previously announced transaction to acquire the net operating assets of R.D. Prabhu-Lata K. Shete MDs, LTD., a Nevada professional corporation d/b/a The Sleep Center of Nevada (“SCN” or “Seller”). T |
|
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2025 (August 19, 2025) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commissio |
|
| August 20, 2025 |
Exhibit 99.1 Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update Quarter highlighted by the key acquisition of The Sleep Center of Nevada, which is generating revenue and seeing strong patient demand for Vivos’ differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., August 19, 2025 |
|
| August 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2025 or ☐ Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period from to Commission File Number: 001-39796 Vivos Ther |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period |
|
| June 13, 2025 |
VIVOS THERAPEUTICS, INC. PRE-FUNDED COMMON STOCK PURCHASE WARRANT Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 13, 2025 |
PRACTICE ADMINISTRATION AGREEMENT Exhibit 10.8 Pursuant to item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. PRACTICE ADMINISTRATION AGREEMENT This PRACTICE ADMINISTRATION AGREEMENT, as it may be amended, modified, or supplemented from time to time ( |
|
| June 13, 2025 |
[Remainder of page intentionally left blank; signature page to follow] Exhibit 10.5 GUARANTY This GUARANTY, made effective as of June 10, 2025, is given by Airway Integrated Management Company, LLC, a Colorado limited liability company (“Guarantor”), for the benefit of Streeterville Capital, LLC, a Utah limited liability company, and its successors, transferees, and assigns (collectively “Investor”). PURPOSE A. Vivos Therapeutics, Inc., a Delaware corporation and par |
|
| June 13, 2025 |
Exhibit 10.6 PLEDGE AGREEMENT This PLEDGE AGREEMENT (this “Agreement”) is entered into as of June 10, 2025 by and between Streeterville Capital, LLC, a Utah limited liability company (the “Secured Party”), and Vivos Therapeutics, Inc., a Delaware corporation (the “Pledgor”). A. Effective as of the date hereof, the Secured Party purchased from Pledgor that certain Secured Promissory Note of even da |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 (June 9, 2025) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commission (I. |
|
| June 13, 2025 |
Exhibit 10.2 Note Purchase Agreement This Note Purchase Agreement (this “Agreement”), dated as of June 10, 2025, is entered into by and between Vivos Therapeutics, Inc., a Delaware corporation (“Company”), and Streeterville Capital, LLC a Utah limited liability company, its successors and/or assigns (“Investor”). A. Company and Investor are executing and delivering this Agreement in reliance upon |
|
| June 13, 2025 |
Exhibit 99.1 Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada Transaction brings OSA diagnostic revenue to Vivos plus Vivos’ highly effective OSA treatment options to thousands of potential patients in the greater Las Vegas area Transaction also completes Vivos’ business model pivot to target high patient volume centers and higher margin revenues Over $11 million in new finan |
|
| June 13, 2025 |
VIVOS THERAPEUTICS, INC. COMMON STOCK PURCHASE WARRANT Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 13, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 9, 2025, between Vivos Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| June 13, 2025 |
PHYSICIAN EMPLOYMENT AGREEMENT Exhibit 10.9 Pursuant to item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. PHYSICIAN EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into as of June 10, 2025 (the “Effective Date” |
|
| June 13, 2025 |
PRACTICE ADMINISTRATION AGREEMENT Exhibit 10.7 Pursuant to item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential PRACTICE ADMINISTRATION AGREEMENT This PRACTICE ADMINISTRATION AGREEMENT, as it may be amended, modified, or supplemented from time to time (c |
|
| June 13, 2025 |
Exhibit 10.4 Security Agreement This Security Agreement (this “Agreement”), dated as of June 10, 2025, is executed by Airway Integrated Management Company, LLC, a Colorado limited liability company (“Guarantor”), in favor of Streeterville Capital, LLC, a Utah limited liability company (“Secured Party”). A. Vivos Therapeutics, Inc., a Delaware corporation and parent company of Guarantor (“Debtor”), |
|
| June 13, 2025 |
Exhibit 10.3 SECURED PROMISSORY NOTE Effective Date: June 10, 2025 U.S. $8,225,000.00 FOR VALUE RECEIVED, Vivos Therapeutics, Inc., a Delaware corporation (“Borrower”), promises to pay to Streeterville Capital, LLC, a Utah limited liability company, or its successors or assigns (“Lender”), $8,225,000.00 and any interest, fees, charges, and late fees accrued provided for hereunder on the date that |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2025 (June 3, 2025) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commission (I.R |
|
| June 6, 2025 |
Exhibit 16.1 June 6, 2025 U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Ladies and Gentlemen: We have read the statements made by Vivos Therapeutics, Inc. included under Item 4.01 of its Current Report on Form 8-K, dated June 6, 2025, to be filed with the Securities and Exchange Commission. We agree with the statements concerning our Firm contained therein. Sincerel |
|
| May 23, 2025 |
Exhibit 4.1 THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER ANY STATE SECURITIES LAW. THE SECURITIES MAY NOT BE OFFERED, SOLD, OR OTHERWISE TRANSFERRED UNLESS THEY ARE REGISTERED UNDER THE ACT AND ALL APPLICABLE STATE SECURITIES LAWS OR ARE IN COMPLIANCE WITH AN EXEMPTION THEREFROM. |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2025 (May 21, 2025) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commission (I.R |
|
| May 23, 2025 |
Exhibit 10.1 SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of May 21, 2025 (as amended, supplemented or otherwise modified from time to time in accordance with the provisions hereof, this “Agreement”), is made by and among Vivos Therapeutics, Inc., a Delaware corporation whose address is 7921 SouthPark Drive, Suite 210, Littleton, CO 80120 (the “Grantor”), in favor of V-CO Investors 2 LLC, |
|
| May 15, 2025 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commission (I.R.S. Employer of |
|
| May 15, 2025 |
Exhibit 99.1 Vivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update Year-over-year product revenue increased 8%, and year-over-year operating expenses decreased 5% as Vivos sets the stage for its Sleep Center of Nevada acquisition and continued advancement of its new marketing and distribution model Management to Host Conference Call today at 5:00 pm ET LIT |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2025 or ☐ Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period from to Commission File Number: 001-39796 Vivos The |
|
| April 17, 2025 |
Exhibit 99.1 Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada By acquiring The Sleep Center of Nevada, Vivos expands its business model to make its OSA treatments available to thousands of patients in the greater Las Vegas metro area Acquisition expected to close later this quarter or in the third quarter LITTLETON, Colo., April 16, 2025 (GLOBE NEWSW |
|
| April 17, 2025 |
Asset Purchase Agreement, dated April 15, 2025, by and among Company, SCN and its shareholders Exhibit 2.1 Portions of this exhibit (indicated by [* * *]) have been omitted because the Company has determined that the information is of the type that the Company treats as private and confidential. ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (this “Agreement”), dated as of April 15, 2025, is entered into by and among R.D. Prabhu-Lata K. Shete MDs, LTD., a Nevada professional corpora |
|
| April 17, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange act of 1934 Date of Report (Date of earliest event reported): April 17, 2025 (April 15, 2025) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction of incorpora |
|
| March 31, 2025 |
Exhibit 21.1 Vivos Therapeutics, Inc. Subsidiaries of the Registrant Entity Name Place of Incorporation First Vivos, Inc. Texas BioModeling Solutions, Inc. Oregon Vivos Therapeutics (Canada) Inc. British Columbia Vivos Management and Development, LLC Colorado Vivos Del Mar Management, LLC California Vivos Therapeutics DSO LLC, a Colorado limited liability company Colorado Vivos Airway Alliance, LL |
|
| March 31, 2025 |
Exhibit 99.1 Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update Year over year product revenue increased 26% Operating expenses declined 21% and year over year operating loss decreased 35% Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., March 31, 2025 – Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading m |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commission (I.R.S. Employer |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2024 ☐ Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period from to Commission File Number: 001-39796 Vivos Therapeutic |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange act of 1934 Date of Report (Date of earliest event reported): February 14, 2025 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction of incorporation or organi |
|
| February 14, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-262554 PROSPECTUS SUPPLEMENT (To Prospectus dated February 14, 2022) Up to $3,328,881 Common Stock Vivos Therapeutics, Inc. (the “Company” or “we”) entered into an At The Market Offering Agreement (the “Agreement”), dated February 14, 2025, with H.C. Wainwright & Co., LLC (“Wainwright”), relating to shares of our common stock, $0.0001 par value |
|
| February 14, 2025 |
Exhibit 10.2 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of the 1st day of January 2025 (the “Effective Date”) by and between VIVOS THERAPEUTICS, INC., a Delaware corporation having its principal place of business at 9137 S. Ridgeline Blvd., Suite 135, Highlands Ranch, Colorado 80129 (th |
|
| February 14, 2025 |
Exhibit 10.3 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of the 1st day of January 2025 (the “Effective Date”) by and between VIVOS THERAPEUTICS, INC., a Delaware corporation having its principal place of business at 9137 S. Ridgeline Blvd., Suite 135, Highlands Ranch, Colorado 80129 (th |
|
| February 14, 2025 |
Exhibit 10.1 AT THE MARKET OFFERING AGREEMENT February 14, 2025 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Vivos Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used in this Agreement and any Ter |
|
| February 11, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Vivos Therapeutics, Inc. |
|
| February 11, 2025 |
As filed with the Securities and Exchange Commission on February 11, 2025 As filed with the Securities and Exchange Commission on February 11, 2025 Registration No. |
|
| February 11, 2025 |
Exhibit 4.5 VIVOS THERAPEUTICS, INC., as ISSUER and [ ], as INDENTURE TRUSTEE INDENTURE Dated as of [ ] TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions 1 Section 1.02 Other Definitions 4 Section 1.03 Incorporation by Reference of Trust Indenture Act 4 Section 1.04 Rules of Construction 4 ARTICLE II THE SECURITIES 5 Section 2.01 Issuable in Ser |
|
| January 31, 2025 |
PROSPECTUS File Pursuant to Rule 424(b)(1) File No. 333-284399 Up to 854,332 shares of Common Stock, Comprised of Up to 709,220 Shares of Common Stock Issuable Upon Exercise of the December 2024 Warrants Up to 145,112 Shares of Common Stock Issuable Upon Exercise of the Placement Agent Warrants This prospectus relates to the offer for sale of up to an aggregate of 854,332 shares of Common Stock, p |
|
| January 29, 2025 |
As filed with the U.S. Securities and Exchange Commission on January 29, 2025 As filed with the U.S. Securities and Exchange Commission on January 29, 2025 Registration No. 333-284399 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 8011 81-3224056 (State or jurisdiction of incorpo |
|
| January 29, 2025 |
VIVOS THERAPEUTICS, INC. 7921 Southpark Plaza, Suite 210 Littleton, Colorado 80120 VIVOS THERAPEUTICS, INC. 7921 Southpark Plaza, Suite 210 Littleton, Colorado 80120 January 29, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Re: Vivos Therapeutics, Inc. Registration Statement on Form S-1, as amended File No. 333-284399 Attention: Conlon Danberg Dear Mr. Danberg: Pursuant to Ru |
|
| January 22, 2025 |
Exhibit 21.1 Vivos Therapeutics, Inc. Subsidiaries of the Registrant Entity Name Place of Incorporation First Vivos, Inc. Texas BioModeling Solutions, Inc. Oregon Vivos Therapeutics (Canada) Inc. British Columbia Vivos Management and Development, LLC Colorado Vivos Del Mar Management, LLC California Vivos Therapeutics DSO LLC, a Colorado limited liability company Colorado Vivos Airway Alliance, LL |
|
| January 22, 2025 |
As filed with the U.S. Securities and Exchange Commission on January 21, 2025 As filed with the U.S. Securities and Exchange Commission on January 21, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 8011 81-3224056 (State or jurisdiction of incorporation or organization) ( |
|
| January 22, 2025 |
Exhibit 107 Calculation of Filing Fee Table S-1 (Form Type) Vivos Therapeutics, Inc. |
|
| December 30, 2024 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| December 26, 2024 |
Prospectus Supplement Filed pursuant to Rule 424(b)(5) (to Prospectus dated February 14, 2022) Registration No. |
|
| December 23, 2024 |
Exhibit 99.1 Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules LITTLETON, Colo., December 23, 2024 – Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathin |
|
| December 23, 2024 |
Form of Placement Agent Warrant (16) Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2024 (December 22, 2024) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commi |
|
| December 23, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| December 23, 2024 |
Form of Purchase Agreement (16) Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 22, 2024, between Vivos Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condit |
|
| November 27, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2024 (November 26, 2024) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commi |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commission (I.R.S. Employ |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2024 or ☐ Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period from to Commission File Number: 001-39796 Vivos |
|
| November 14, 2024 |
Exhibit 99.1 Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update Revenue Increased 17% Quarter over Quarter Operating Loss Decreased 27% Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., November 14, 2024 – Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializ |
|
| November 14, 2024 |
VVOS / Vivos Therapeutics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-vvos093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Vivos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92859E207 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) C |
|
| November 14, 2024 |
VVOS / Vivos Therapeutics, Inc. / Ionic Ventures, LLC - SC 13G/A Passive Investment SC 13G/A 1 g084558sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Vivos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92859E207 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the app |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Ru |
|
| October 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Ru |
|
| September 24, 2024 |
VVOS / Vivos Therapeutics, Inc. / Ionic Ventures, LLC - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Vivos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92859E207 (CUSIP Number) September 19, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| September 20, 2024 |
Prospectus Supplement Filed pursuant to Rule 424(b)(5) (to Prospectus dated February 14, 2022) Registration No. |
|
| September 20, 2024 |
Form of Purchase Agreement (15) Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 18, 2024, between Vivos Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condi |
|
| September 20, 2024 |
Exhibit 99.1 Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules LITTLETON, Colo., September 19, 2024 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective prop |
|
| September 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2024 (September 18, 2024) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Com |
|
| September 20, 2024 |
Form of Placement Agent Warrant (15) Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| September 18, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2024 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commission (I.R.S. Emplo |
|
| September 18, 2024 |
Exhibit 99.1 Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model Vivos’ DNA appliance now approved to reduce snoring and treat moderate to severe OSA in chil |
|
| September 17, 2024 |
Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange act of 1934 Date of Report (Date of earliest event reported): September 17, 2024 (September 12, 2024) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction of i |
|
| September 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange act of 1934 Date of Report (Date of earliest event reported): September 12, 2024 (September 7, 2024) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction of in |
|
| August 15, 2024 |
Exhibit 99.1 Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update Revenue Increased 19% both Sequentially and Year over Year Operating Expenses Decreased 31%, Marking Eight Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting Initiatives Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., August 14, 2024 |
|
| August 15, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commission (I.R.S. Employer |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2024 Or ☐ Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period from to Commission File Number: 001-39796 Vivos Ther |
|
| August 14, 2024 |
V-CO Investors, LLC Common Stock Purchase Warrant Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 14, 2024 |
Exhibit 10.2 EXECUTION VERSION CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS EITHER (i) NOT MATERIAL AND (ii) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL, OR DISCLOSURE OF SUCH INFORMATION WOULD CONSTITUTE A CLEARLY UNWARRANTED INVASION OF PERSONAL PRIVACY. REDACTED INFORMATION IS MARKED WITH A [*****] Strategic Alliance Agreement This Strate |
|
| August 14, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 10, 2024, between Vivos Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and condition |
|
| August 14, 2024 |
Exhibit 10.3 EXECUTION VERSION CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS EITHER (i) NOT MATERIAL AND (ii) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL, OR DISCLOSURE OF SUCH INFORMATION WOULD CONSTITUTE A CLEARLY UNWARRANTED INVASION OF PERSONAL PRIVACY. REDACTED INFORMATION IS MARKED WITH A [*****] MANAGEMENT SERVICES AGREEMENT THIS MANAG |
|
| August 14, 2024 |
V-CO Investors, LLC Pre-Funded Common Stock Purchase Warrant EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 8, 2024 |
PROSPECTUS Filed Pursuant to Rule 424(b)(1) File No. 333-281090 169,498 Shares of Common Stock 3,050,768 Shares of Common Stock Issuable Upon Exercise of Pre-Funded Warrant 3,220,266 Shares of Common Stock Issuable Upon Exercise of Common Stock Purchase Warrant This prospectus relates to the resale by the selling stockholder named herein, including its transferees, assigns, pledgees or donees, or |
|
| August 5, 2024 |
Vivos therapeautics, Inc. 7921 Southpark Plaza, Suite 210 Littleton, Colorado 80120 Vivos therapeautics, Inc. 7921 Southpark Plaza, Suite 210 Littleton, Colorado 80120 August 5, 2024 VIA EDGAR U.S. SECURITIES AND EXCHANGE COMMISSION Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Margaret Sawicki Re: Vivos Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-281090 Filed July 30, 2024 Dear Ms. Sawicki: Pursuant to Rule 461 under th |
|
| July 30, 2024 |
Pre-Funded Warrant, dated June 10, 2024, issued to V-CO Investors LLC. (13) Exhibit 4.12 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2023 ☐ Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period from to Commission File Number: 001-397 |
|
| July 30, 2024 |
Warrant, dated June 10, 2024, issued to V-CO Investors LLC. (13) Exhibit 4.13 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| July 30, 2024 |
Exhibit 107 Calculation of Filing Fee Table S-3 (Form Type) Vivos Therapeutics, Inc. |
|
| July 30, 2024 |
As filed with the Securities and Exchange Commission on July 29, 2024 As filed with the Securities and Exchange Commission on July 29, 2024 Registration No. |
|
| July 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange act of 1934 Date of Report (Date of earliest event reported): July 10, 2024 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction of incorporation or organizati |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction of incorporation or organizati |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 (June 10, 2024) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction of incorporati |
|
| June 14, 2024 |
Exhibit 99.1 Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance Alliance with Sleep Treatment Provider in Colorado Marks Critical Pivot in Vivos’ Marketing and Distribution Model Aimed at Enhancing Revenue Streams and Potential Profit Private Placement Investment Sponsored by Seneca Partners, Who Will Als |
|
| May 17, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange act of 1934 Date of Report (Date of earliest event reported): May 17, 2024 (May 16, 2024) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction of incorporation |
|
| May 15, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 (May 14, 2024) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commission (I.R |
|
| May 15, 2024 |
Exhibit 99.1 Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update Vivos Expanding its Revenue Generating Initiatives As Operating Expenses Decrease 22%, Representing Seven Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting Initiatives Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., May 14, 2024 – Viv |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2024 or ☐ Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period from to Commission File Number: 001-39796 Vivos The |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange act of 1934 Date of Report (Date of earliest event reported): May 3, 2024 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction of incorporation or organization |
|
| April 26, 2024 |
PROSPECTUS Filed Pursuant to Rule 424(b)(1) File No. 333-278564 1,737,259 shares common stock This prospectus relates to the offer for sale of up to an aggregate of 1,737,259 shares of common stock, par value $0.0001 per share (or the Common Stock), of Vivos Therapeutics, Inc. by the selling stockholder named herein (who we refer to as the selling stockholder), which is comprised of: (i) 266,667 s |
|
| April 24, 2024 |
Vivos therapeautics, Inc. 7921 Southpark Plaza, Suite 210 Littleton, Colorado 80120 Vivos therapeautics, Inc. 7921 Southpark Plaza, Suite 210 Littleton, Colorado 80120 April 24, 2024 VIA EDGAR U.S. SECURITIES AND EXCHANGE COMMISSION Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Jane Park Re: Vivos Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-278564 Filed April 9, 2024, as amended Dear Mr. Richie: Pursuant to Rule 461 unde |
|
| April 22, 2024 |
As filed with the U.S. Securities and Exchange Commission on April 19, 2024 As filed with the U.S. Securities and Exchange Commission on April 19, 2024 Registration No. 333-278564 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 8011 81-3224056 (State or jurisdiction of incorpora |
|
| April 9, 2024 |
As filed with the U.S. Securities and Exchange Commission on April 8, 2024 As filed with the U.S. Securities and Exchange Commission on April 8, 2024 Registration No. 333-[] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 8011 81-3224056 (State or jurisdiction of incorporation or organization) (P |
|
| April 9, 2024 |
Exhibit 107 Calculation of Filing Fee Table S-1 (Form Type) Vivos Therapeutics, Inc. |
|
| March 29, 2024 |
Exhibit 99.1 Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update Positive Business Momentum and Sales Pipeline Growth Following FDA 510(k) Clearance of Vivos’ Proprietary Oral Medical Devices to Treat Severe Obstructive Sleep Apnea Annual Operating Expenses Declined 27% Due to Success of Cost Cutting Initiatives Management to Host Conferen |
|
| March 29, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commission (I.R.S. Employer |
|
| March 28, 2024 |
Exhibit 21.1 Vivos Therapeutics, Inc. Subsidiaries of the Registrant Entity Name Place of Incorporation First Vivos, Inc. Texas BioModeling Solutions, Inc. Oregon Vivos Therapeutics (Canada) Inc. British Columbia Vivos Management and Development, LLC Colorado Vivos Del Mar Management, LLC California Vivos Modesto Management, LLC California Vivos Therapeutics DSO LLC, a Colorado limited liability c |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2023 ☐ Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period from to Commission File Number: 001-39796 Vivos Therapeutic |
|
| March 28, 2024 |
Exhibit 97.1 VIVOS THERAPEUTICS, INC. EXECUTIVE COMPENSATION CLAWBACK POLICY Adopted as of December 1, 2023 The Board of Directors (the “Board”) of Vivos Therapeutics, Inc. (the “Company”) has adopted the following executive compensation clawback policy (this “Policy”). This Policy shall supplement any other clawback or compensation recovery policy or policies adopted by the Company or included in |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange act of 1934 Date of Report (Date of earliest event reported): February 15, 2024 (February 14, 2024) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction of (Co |
|
| February 15, 2024 |
EXHIBIT 10.1 VIVOS THERAPEUTICS, INC. 7921 Southpark Plaza, Suite 210 Littleton, CO 80120 February 14, 2024 To the Holder of Series B Common Stock Purchase Warrants of Vivos Therapeutics, Inc. Issued on November 2, 2023 Re: Warrant Inducement Agreement Dear Holder: VIVOS THERAPEUTICS, INC. (the “Company”) is pleased to offer (this “Offer”) to you (“Holder”, “you” or similar terminology) the opport |
|
| February 15, 2024 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 15, 2024 |
EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 15, 2024 |
590 Madison Avenue, 28th Floor, New York, NY 10022, 212-624-2060 Member FINRA, SIPC Exhibit 99.1 February 14, 2024 CONFIDENTIAL Vivos Therapeutics, Inc. Attention: Bradford K. Amman 7921 Southpark Plaza, Suite 210 Littleton, CO 80120 The purpose of this financial advisory agreement (this “Agreement”) is to confirm the engagement of A.G.P./Alliance Global Partners (“A.G.P.”) by Vivos Therapeutics, Inc. (the “Company”) to render Financial Services (as defined below) to the Company. |
|
| February 14, 2024 |
US92859E2072 / VIVOS THERAPEUTICS INC / Huntsman Ronald Kirk Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A (Amendment No. 3) UNDER THE SECURITIES EXCHANGE ACT OF 1934 VIVOS THERAPEUTICS, INC. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 92859E207 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the app |
|
| February 14, 2024 |
US92859E2072 / VIVOS THERAPEUTICS INC / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-vvos123123.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Vivos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92859E207 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the |
|
| December 1, 2023 |
PROSPECTUS Filed Pursuant to Rule 424(b)(1) File No. 333-275726 2,941,179 shares common stock This prospectus relates to the offer for sale of up to an aggregate of 2,941,179 shares of common stock, par value $0.0001 per share, of Vivos Therapeutics, Inc., by the stockholder named herein (who we refer to as the selling stockholder), which is comprised of: (i) 130,000 shares of common stock, (ii) 8 |
|
| November 30, 2023 |
As filed with the U.S. Securities and Exchange Commission on November 30, 2023 As filed with the U.S. Securities and Exchange Commission on November 30, 2023 Registration No. 333-275726 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A (Amendment No. 1) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 8011 81-3224056 (State or jurisdiction of incor |
|
| November 30, 2023 |
Vivos therapeautics, Inc. 7921 Southpark Plaza, Suite 210 Littleton, Colorado 80120 Vivos therapeautics, Inc. 7921 Southpark Plaza, Suite 210 Littleton, Colorado 80120 November 30, 2023 VIA EDGAR U.S. SECURITIES AND EXCHANGE COMMISSION Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Ben Richie Re: Vivos Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-275726 Filed November 22, 2023 Dear Mr. Richie: Pursuant to Rule 461 under th |
|
| November 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange act of 1934 Date of Report (Date of earliest event reported): November 30, 2023 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction of incorporation or organi |
|
| November 22, 2023 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table S-1 (Form Type) Vivos Therapeutics, Inc. |
|
| November 22, 2023 |
As filed with the U.S. Securities and Exchange Commission on November 22, 2023 As filed with the U.S. Securities and Exchange Commission on November 22, 2023 Registration No. 333-[ ] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 8011 81-3224056 (State or jurisdiction of incorporation or organizatio |
|
| November 22, 2023 |
Exhibit 21.1 Vivos Therapeutics, Inc. Subsidiaries of the Registrant Entity Name Place of Incorporation First Vivos, Inc. Texas BioModeling Solutions, Inc. Oregon Vivos Therapeutics (Canada) Inc. British Columbia Vivos Management and Development, LLC Colorado Vivos Del Mar Management, LLC California Vivos Modesto Management, LLC California Vivos Therapeutics DSO LLC, a Colorado limited liability c |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2023 or ☐ Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period from to Commission File Number: 001-39796 Vivos |
|
| November 3, 2023 |
Filed Pursuant to Rule 424(b)(3) File No. 333-269453 PROSPECTUS SUPPLEMENT NO. 1 TO PROSPECTUS, DATED FEBRUARY 8, 2023 533,334 Shares Common Stock This prospectus supplement amends and supplements the prospectus, dated February 8, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (No. 333-269453). This prospectus supplement is being filed to update and supplemen |
|
| November 2, 2023 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| November 2, 2023 |
Exhibit 10.2 FORM OF REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of November [ ], 2023, between Vivos Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Secur |
|
| November 2, 2023 |
Exhibit 4.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 (October 30, 2023) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction of incor |
|
| November 2, 2023 |
Exhibit 4.3 November , 2023 To: Armistice Capital Master Fund Ltd. (the “Holder”) Re: Amendment to Common Stock Purchase Warrant, dated January 9, 2023, issued by the Company to the Holder (the “January 2023 Warrant”) Dear Holder: Reference is hereby made to the private placement offering, closing on or about the date hereof (the “Offering”), by Vivos Therapeutics, Inc. (the “Company”) of shares o |
|
| November 2, 2023 |
Exhibit 10.3 PLACEMENT AGENCY AGREEMENT October 30, 2023 Vivos Therapeutics, Inc. 7921 SouthPark Drive, Suite 210 Littleton, CO 80120 Attn: R. Kirk Huntsman, Chairman and Chief Executive Officer Dear Mr. Huntsman: This letter (this “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and Vivos Therapeutics, Inc., a Delaware corporation (the “Compan |
|
| November 2, 2023 |
Exhibit 10.1 VIVOS therapeutics, INC. FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 30, 2023, between Vivos Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS |
|
| November 2, 2023 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 27, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF VIVOS THERAPEUTICS, INC. Vivos Therapeutics, Inc. (the “Corporation”), a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: 1. The name of the Corporation is: Vivos Therapeutics, Inc. 2. The board of directors of the Corporation (the “B |
|
| October 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2023 (October 25, 2023) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commiss |
|
| September 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2023 (September 22, 2023) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Com |
|
| September 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2023 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commission (I.R.S. Emplo |
|
| September 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Ru |
|
| September 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Ru |
|
| August 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Ru |
|
| August 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2023 (August 17, 2023) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commissio |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Ru |
|
| August 16, 2023 |
Exhibit 99.1 Vivos Therapeutics Reports Second Quarter 2023 Financial Results and Provides Operational Update Operating Expenses Decreased 31% Quarter Over Quarter and 25% Year to Date, Reflecting Cost Cutting Initiatives Management to Host Conference Call Today at 6:00 pm ET LITTLETON, Colo., August 16, 2023 – Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a medical technolo |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2023 or ☐ Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period from to Commission File Number: 001-39796 Vivos Ther |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2023 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commission (I.R.S. Employer |
|
| August 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-K ☐ Transition Report on Fo |
|
| June 8, 2023 |
Exhibit 99.1 Vivos Therapeutics Reports First Quarter 2023 Financial Results and Provides Operational Update Revenue increased 6% Year-Over-Year; Operating Expenses Decreased 20% as Cost Cutting Initiatives Take Hold Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., June 8, 2023 – Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a medical technology compa |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2023 or ☐ Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period from to Commission File Number: 001-39796 Vivos The |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commission (I.R.S. Employer of |
|
| May 26, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2023 (May 23, 2023) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commission (I.R |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-K ☐ Transition Report on F |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 (May 3, 2023) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commission (I.R.S |
|
| May 9, 2023 |
Letter to the Securities and Exchange Commission from Plante & Moran, PLLC Exhibit 16.1 Plante & Moran, PLLC Suite 600 8181 E. Tufts Avenue Denver, CO 80237 Tel: 303.740.9400 Fax: 303.740.9009 plantemoran.com May 9, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners, We have read the Item 4.01 included in the Form 8-K of Vivos Therapeutics, Inc., which we understand will be filed with the Securities and Exchange Commission on or |
|
| May 9, 2023 |
Exhibit 99.1 Vivos Therapeutics Announces Additional Strategic Initiatives Aimed at Accelerating Anticipated Timeline for Cash Flow Positive Operations Moss Adams LLP also appointed as new independent registered public accounting firm LITTLETON, CO, May 9, 2023 — Vivos Therapeutics, Inc. (“Vivos”, “the Company”) (NASDAQ:VVOS) today announced it has implemented a broad set of initiatives aimed at i |
|
| March 30, 2023 |
Exhibit 99.1 Vivos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Operational Update 2022 and Early 2023 Accomplishments, Including Capital Raise, Cost Reductions and New Technology Acquisition, Set the Stage for Potential 2023 Revenue Growth Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., March 30, 2023 – Vivos Therapeutics, Inc. (“V |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2022 ☐ Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period from to Commission File Number: 001-39796 Vivos Therapeutic |
|
| March 30, 2023 |
Exhibit 21.1 Vivos Therapeutics, Inc. Subsidiaries of the Registrant Entity Name Place of Incorporation First Vivos, Inc. Texas BioModeling Solutions, Inc. Oregon Vivos Therapeutics (Canada) Inc. British Columbia Vivos Management and Development, LLC Colorado Vivos Del Mar Management, LLC California Vivos Modesto Management, LLC California Vivos Therapeutics DSO LLC, a Colorado limited liability c |
|
| March 30, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commission (I.R.S. Employer |
|
| March 30, 2023 |
Insider Trading Policy and Compliance Manual (10) Exhibit 99.1 Insider Trading Compliance Manual VIVOS THERAPEUTICS, INC. Adopted: March 29, 2023 In order to take an active role in the prevention of insider trading violations by its officers, directors, employees, consultants, attorneys, advisors and other related individuals, the Board of Directors (the “Board”) of Vivos Therapeutics, Inc., a Delaware corporation (the “Company”), has adopted the |
|
| March 27, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2023 (March 24, 2023) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commission |
|
| March 2, 2023 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 2, 2023 (February 28, 2023) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction of incorpo |
|
| March 2, 2023 |
Exhibit 99.1 For Immediate Release Vivos Therapeutics Expands Product Line and Revenue Potential with Acquisition of Product Rights and Patents from Advanced Facialdontics, LLC Acquisition Adds Complementary, Lower Cost Products for Treating Conditions Associated with Obstructive Sleep Apnea LITTLETON, CO, March 1, 2023 — Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical |
|
| February 10, 2023 |
VVOS / Vivos Therapeutics Inc / Huntsman Ronald Kirk Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A (Amendment No. 2) UNDER THE SECURITIES EXCHANGE ACT OF 1934 VIVOS THERAPEUTICS, INC. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 92859108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 10, 2023 |
13,333,334 shares common stock PROSPECTUS Filed Pursuant to Rule 424(b)(1) File No. 333-269453 13,333,334 shares common stock This prospectus relates to the offer for sale of up to an aggregate of 13,333,334 shares of common stock, par value $0.0001 per share, of Vivos Therapeutics, Inc., by the stockholder of our company named herein (who we refer to as the selling stockholder), which is comprised of: (i) 2,000,000 shares of c |
|
| February 6, 2023 |
Vivos therapeautics, Inc. 7921 Southpark Plaza, Suite 210 Littleton, Colorado 80120 Vivos therapeautics, Inc. 7921 Southpark Plaza, Suite 210 Littleton, Colorado 80120 February 6, 2023 VIA EDGAR U.S. SECURITIES AND EXCHANGE COMMISSION Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Margaret Schwartz Re: Vivos Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-269453 Filed January 30, 2023 Dear Ms. Schwartz: Pursuant to Rule 461 u |
|
| January 30, 2023 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table S-1 (Form Type) Vivos Therapeutics, Inc. |
|
| January 30, 2023 |
As filed with the U.S. Securities and Exchange Commission on January 27, 2023 As filed with the U.S. Securities and Exchange Commission on January 27, 2023 Registration No. 333-[ ] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 8011 81-3224056 (State or jurisdiction of incorporation or organization |
|
| January 30, 2023 |
Exhibit 21.1 Vivos Therapeutics, Inc. Subsidiaries of the Registrant Entity Name Place of Incorporation First Vivos, Inc. Texas BioModeling Solutions, Inc. Oregon Vivos Therapeutics (Canada) Inc. British Columbia Vivos Management and Development, LLC Colorado Vivos Del Mar Management, LLC California Vivos Modesto Management, LLC California Vivos Therapeutics DSO LLC, a Colorado limited liability c |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 (January 5, 2023) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction of incorpo |
|
| January 9, 2023 |
Exhibit 10.3 PLACEMENT AGENCY AGREEMENT Vivos Therapeutics, Inc. January 5, 2023 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Vivos Therapeutics, Inc., a Delaware corporation (the |
|
| January 9, 2023 |
Exhibit 10.1 VIVOS therapeutics, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 5, 2023, between Vivos Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject |
|
| January 9, 2023 |
Vivos Therapeutics Announces Pricing of $8 Million Private Placement Exhibit 99.1 Vivos Therapeutics Announces Pricing of $8 Million Private Placement LITTLETON, Colo., Jan. 05, 2023 — Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults, today annou |
|
| January 9, 2023 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 9, 2023 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 9, 2023 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of January 5, 2023, between Vivos Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purch |
|
| December 20, 2022 |
Exhibit 99.1 For Immediate Release Vivos Therapeutics Reports Second and Third Quarter 2022 Financial Results and Provides Operational Update Second and Third Quarter 10-Q Filings Bring Vivos Current on SEC Filings for Nasdaq Stock Market Purposes Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., December 20, 2022 ? Vivos Therapeutics, Inc. (?Vivos? or the ?Company??) (NASDA |
|
| December 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-39796 Vivos |
|
| December 20, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 20, 2022 Vivos Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-39796 81-3224056 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| December 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-39796 Vivos Ther |
|
| November 29, 2022 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 Vivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Third Quarter 2022 Quarterly Report on Form 10-Q Vivos expects to become current on its SEC filings in the coming weeks LITTLETON, COLORADO—November 28, 2022—Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or the “Company”) today announced that it has received a notice (“Notice”) |
|
| November 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2022 (November 16, 2022) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commi |
|
| November 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No.1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No.1) (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: |
|
| November 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 22, 2022 (November 18, 2022) Vivos Therapeutics, Inc. |
|
| November 22, 2022 |
Exhibit 99.1 Vivos Therapeutics Provides Update on Revenue Recognition Review Detailed Analysis Finds Minimal Impact on Prior Financial Results; No Previously Reported Revenue to be Lost Previously Reported First Quarter 2022 Revenue Expected to Increase Approximately $200,000; No Need to Restate Prior Year Financial Statements Restated First Quarter 2022 Results to be Filed Shortly; Second and Th |
|
| November 4, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2022 (November 3, 2022) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commiss |
|
| August 26, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2022 (August 25, 2022) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commissio |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-K ? Transition Report on Fo |
|
| July 18, 2022 |
Exhibit 99.1 Vivos Therapeutics Announces Multiple Regulatory Clearances in Australia for its Entire Line of Oral Appliances Australia clears Vivos technology to treat obstructive sleep apnea for all ages and regardless of severity in broad regulatory win. LITTLETON, COLO., JULY 14, 2022 - Vivos Therapeutics, Inc. (NASDAQ: VVOS) is pleased to announce that it has received multiple Class I clearanc |
|
| July 18, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 15, 2022 (July 14, 2022) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction of incorporati |
|
| July 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (As Permitted by Ru |
|
| June 15, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 15, 2022 (June 14, 2022) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction of incorporati |
|
| June 15, 2022 |
Exhibit 99.1 Vivos Therapeutics’ SLEEP 2022 Annual Meeting Presentation Highlights Retrospective Study Demonstrating Significant Improvement in Sleep Apnea Study Recently Presented at the SLEEP 2022 Annual Meeting LITTLETON, COLO., JUNE 14, 2022 – Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or “the Company”), a revenue-generating medical technology company focused on developing innovative tre |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-39796 Vivos The |
|
| May 16, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 16, 2022 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction of incorporation) (Commission F |
|
| May 16, 2022 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 For Immediate Release Vivos Therapeutics Reports First Quarter 2022 Financial Results and Operational Update First Quarter Appliance Revenue Increased 19% Year-Over-Year Management to Host Conference Call Today at 5:00 pm ET HIGHLANDS RANCH, Colo., May 16, 2022 – Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a medical technology company focu |
|
| March 31, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2022 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction of incorporation) (Commission |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2021 ? Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period from to Commission File Number: 001-39796 Vivos Therapeutic |
|
| March 31, 2022 |
Exhibit 99.1 For Immediate Release Vivos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update Fourth Quarter Revenue Increased 33% Year-Over-Year While Full Year Revenue Increased 29% Management to Host Conference Call Today at 5:00 pm ET HIGHLANDS RANCH, Colo., March 31, 2022 ? Vivos Therapeutics, Inc. (?Vivos? or the ?Company??) (NASDAQ: VVOS), a medica |
|
| March 31, 2022 |
EXHIBIT 21.1 Vivos Therapeutics, Inc. Subsidiaries of the Registrant Entity Name Place of Incorporation First Vivos, Inc. Texas BioModeling Solutions, Inc. Oregon Vivos Therapeutics (Canada) Inc. British Columbia Vivos Management and Development, LLC Colorado Vivos Del Mar Management, LLC California Vivos Modesto Management, LLC California Vivos Therapeutics, DSO LLC, a Colorado limited liability |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 1, 2022 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction of incorporation) (Commission |
|
| February 14, 2022 |
VVOS / Vivos Therapeutics Inc / Huntsman Ronald Kirk Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A (Amendment No. 1) UNDER THE SECURITIES EXCHANGE ACT OF 1934 VIVOS THERAPEUTICS, INC. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 92859E108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 14, 2022 |
Vivos Therapeutics, Inc. 9137 S. Ridgeline Boulevard, Suite 135 Highlands Ranch, Colorado 80129 Vivos Therapeutics, Inc. 9137 S. Ridgeline Boulevard, Suite 135 Highlands Ranch, Colorado 80129 February 14, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Vivos Therapeutics Inc. Registration Statement on Form S-3 Filed February 7, 2022 File No. 333-262554 Ladies and Gentlemen: Pursuant to Rule 461 of t |
|
| February 14, 2022 |
VVOS / Vivos Therapeutics Inc / Singh Gurdev Dave Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A (Amendment No. 1) UNDER THE SECURITIES EXCHANGE ACT OF 1934 VIVOS THERAPEUTICS, INC. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 92859E108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 7, 2022 |
Exhibit 4.5 VIVOS THERAPEUTICS, INC., as ISSUER and [ ], as INDENTURE TRUSTEE INDENTURE Dated as of [ ] TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions 1 Section 1.02 Other Definitions 4 Section 1.03 Incorporation by Reference of Trust Indenture Act 4 Section 1.04 Rules of Construction 4 ARTICLE II THE SECURITIES 5 Section 2.01 Issuable in Ser |
|
| February 7, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Vivos Therapeutics, Inc. |
|
| February 7, 2022 |
Sales Agreement dated February 7, 2022, between the Company and Roth Capital Partners, LLC.(6) EX-1.2 2 ex1-2.htm Exhibit 1.2 Vivos Therapeutics, Inc. 9137 S Ridgeline Blvd #135 Highlands Ranch, CO 80129 Up to $10,000,000 Common Stock ($0.0001 par value per share) Sales Agreement February 7, 2022 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Vivos Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement ( |
|
| February 7, 2022 |
As filed with the Securities and Exchange Commission on February 7, 2022 As filed with the Securities and Exchange Commission on February 7, 2022 Registration No. |
|
| November 15, 2021 |
Exhibit 99.1 For Immediate Release Vivos Therapeutics Reports Third Quarter 2021 Financial Results and Operational Update Third Quarter Revenue Increased Over 38% Year-Over-Year Expects to Benefit from Increased OSA Testing, Opening of Live Training Facility, Expansion of Marketing Programs, Additional FDA Approval and Positive Study Results Management to Host Conference Call Today at 5:00 pm ET H |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39796 Vivos |
|
| November 15, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 15, 2021 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction of incorporation) (Commiss |
|
| September 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2021 (September 22, 2021) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Com |
|
| September 27, 2021 |
Exhibit 10.1 SABBATICAL AGREEMENT This SABBATICAL AGREEMENT (this ?Agreement?) is made and entered into as of the 22nd day of September, 2021 (the ?Effective Date?) by and between VIVOS THERAPEUTICS, INC., a Delaware corporation having its principal place of business at 9137 S. Ridgeline Blvd., Suite 135, Highlands Ranch, Colorado 80129 (the ?Company?) and DR. G. DAVE SINGH, an individual currentl |
|
| August 12, 2021 |
Exhibit 99.1 For Immediate Release Vivos Therapeutics Reports Second Quarter 2021 Financial Results and Operational Update Second Quarter Revenue Increased Over 37% Year-Over-Year and 30% Over Q1 2021 Management to Host Conference Call Today at 5:00 pm ET HIGHLANDS RANCH, Colo., August 12, 2021 ? Vivos Therapeutics, Inc. (?the Company?) (NASDAQ: VVOS), a medical technology company focused on devel |
|
| August 12, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 12, 2021 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction of incorpo |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39796 Vivos Ther |
|
| July 29, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 (July 28, 2021) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commission (I |
|
| June 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] |
|
| June 17, 2021 |
Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 17, 2021 (June 16, 2021) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction of incorporati |
|
| June 11, 2021 |
As filed with the Securities and Exchange Commission on June 11, 2021 As filed with the Securities and Exchange Commission on June 11, 2021 Registration No. |
|
| May 19, 2021 |
PROSPECTUS Filed Pursuant to Rule 424(b)(4) File No. 333-255553 File No. 333-249412 VIVOS THERAPEUTICS, INC. 9,710,010 shares common stock 402,500 shares of common stock underlying a previously issued underwriter warrants This prospectus relates to (i) the offer for sale of up to an aggregate of 9,710,010 shares of common stock, par value $0.0001 per share, of Vivos Therapeutics, Inc., by certain |
|
| May 18, 2021 |
Vivos Therapeutics, Inc. 9137 South Ridgeline Boulevard, Suite 135 Highlands Ranch, Colorado 80129 Vivos Therapeutics, Inc. 9137 South Ridgeline Boulevard, Suite 135 Highlands Ranch, Colorado 80129 May 18, 2021 VIA EDGAR U.S. SECURITIES AND EXCHANGE COMMISSION Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Alan Campbell Re: Vivos Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-255553) Dear Mr. Campbell: Pursuant to Rule 461 under the Secur |
|
| May 18, 2021 |
As filed with the U.S. Securities and Exchange Commission on May 18, 2021 As filed with the U.S. Securities and Exchange Commission on May 18, 2021 Registration No. 333-255553 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 8011 81-3224056 (State or jurisdiction of incorporati |
|
| May 17, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 17, 2021 (May 17, 2021) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction of incorporation |
|
| May 17, 2021 |
Exhibit 99.1 For Immediate Release Vivos Therapeutics Reports First Quarter 2021 Financial Results and Operational Update Management to Host Conference Call Today at 5:00 pm ET HIGHLANDS RANCH, Colo., May 17, 2021 ? Vivos Therapeutics, Inc. (the ?Company? or ?Vivos?) (NASDAQ:VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39796 Vivos |
|
| May 12, 2021 |
Form of Representative’s Warrant in connection with the Company’s May 2021 follow-on offering. (5) Exhibit 4.1 THE REGISTERED HOLDER OF THIS WARRANT AGREES BY HIS, HER OR ITS ACCEPTANCE HEREOF, THAT SUCH HOLDER WILL NOT FOR A PERIOD OF ONE HUNDRED EIGHTY (180) DAYS FOLLOWING THE EFFECTIVE DATE (THE ?EFFECTIVE DATE?) OF THE REGISTRATION STATEMENT (AS DEFINED BELOW): (A) SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS WARRANT TO ANYONE IN ACCORDANCE WITH FINRA RULE 5110(E)(1)(A), AND (B) CAUSE |
|
| May 12, 2021 |
Exhibit 99.1 Vivos Therapeutics Announces Closing of Follow-On Offering and Exercise in Full of the Underwriters? Option to Purchase Additional Shares HIGHLANDS RANCH, Colo., May 11, 2021 ? Vivos Therapeutics, Inc. (Nasdaq: VVOS) (?Vivos?), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including |
|
| May 12, 2021 |
Exhibit 1.1 Vivos Therapeutics, Inc. UNDERWRITING AGREEMENT 4,000,000 Shares of Common Stock May 6, 2021 Roth Capital Partners, LLC As Representative of the Several Underwriters Named on Schedule I hereto 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Vivos Therapeutics, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions sta |
|
| May 12, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 12, 2021 (May 6, 2021) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction of (Commission (I |
|
| May 10, 2021 |
4,000,000 shares Vivos Therapeutics, Inc. Common Stock PROSPECTUS Filed Pursuant to Rule 424(b)(4) File No. 333-255736 File No. 333-255855 4,000,000 shares Vivos Therapeutics, Inc. Common Stock We are offering 4,000,000 shares of our common stock on an underwritten, firm commitment basis. Our common stock is listed on Nasdaq under the symbol ?VVOS?. On May 6, 2021, the last reported sales price of a share of our common stock on Nasdaq was $6.43. We ha |
|
| May 6, 2021 |
S-1MEF 1 forms-1mef.htm As filed with the Securities and Exchange Commission on May 6, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VIVOS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 8011 81-3224056 (State or jurisdiction of incorporation or o |
|
| May 4, 2021 |
May 4, 2021 VIA EDGAR Mr. Alan Campbell Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, DC 20549 Re: Vivos Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-255736) Dear Mr. Campbell: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the ?Securities Act?), we hereby join in the request of Vivos Therapeuti |
|
| May 4, 2021 |
Vivos Therapeutics, Inc. 9137 South Ridgeline Boulevard, Suite 135 Highlands Ranch, Colorado 80129 Vivos Therapeutics, Inc. 9137 South Ridgeline Boulevard, Suite 135 Highlands Ranch, Colorado 80129 May 4, 2021 VIA EDGAR U.S. SECURITIES AND EXCHANGE COMMISSION Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Alan Campbell Re: Vivos Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-255736) Dear Mr. Campbell: Pursuant to Rule 461 under the Securi |
|
| May 3, 2021 |
Form of Underwriting Agreement Exhibit 1.1 Vivos Therapeutics, Inc. UNDERWRITING AGREEMENT [?] Shares of Common Stock [?], 2021 Roth Capital Partners, LLC As Representative of the Several Underwriters Named on Schedule I hereto 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Vivos Therapeutics, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated here |
|
| May 3, 2021 |
Form of Representative’s Warrant Exhibit 4.3 THE REGISTERED HOLDER OF THIS WARRANT AGREES BY HIS, HER OR ITS ACCEPTANCE HEREOF, THAT SUCH HOLDER WILL NOT FOR A PERIOD OF ONE HUNDRED EIGHTY (180) DAYS FOLLOWING THE EFFECTIVE DATE (THE ?EFFECTIVE DATE?) OF THE REGISTRATION STATEMENT (AS DEFINED BELOW): (A) SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS WARRANT TO ANYONE IN ACCORDANCE WITH FINRA RULE 5110(E)(1)(A), AND (B) CAUSE |
|
| May 3, 2021 |
As filed with the U.S. Securities and Exchange Commission on May 3, 2021 Registration No. 333? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VIVOS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 8011 81-3224056 (State or other jurisdiction of incorporation or organization) |
|
| April 27, 2021 |
S-1 1 forms-1.htm As filed with the U.S. Securities and Exchange Commission on April 27, 2021 Registration No. 333-[ ] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 8011 81-3224056 (State or jurisdiction of incorporation |
|
| April 13, 2021 |
This is a confidential draft submission to the U.S. Securities and Exchange Commission pursuant to Section 106(a) of the Jumpstart Our Business Startups Act of 2012 on April 13, 2021 and is not being filed publicly under the Securities Act of 1933, as amended. Registration No. 333? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SEC |
|
| April 2, 2021 |
Exhibit 99.1 For Immediate Release Vivos Therapeutics to Launch MyoCorrect Orofacial Myofunctional Therapy Service Vivos to offer MyoCorrect via telemedicine for all Vivos-trained clinicians to use as therapeutic protocol in tandem with the Vivos System HIGHLANDS RANCH, Colo., March 30, 2021 ? Vivos Therapeutics, Inc. (the ?Company? or ?Vivos?) (NASDAQ: VVOS), a medical technology company focused |
|
| April 2, 2021 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 2, 2021 (March 29, 2021) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction of incorporat |
|
| March 25, 2021 |
Exhibit 99.1 For Immediate Release Vivos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update Full Year Revenue Increase of 15% Management to Host Conference Call Today at 5:00 pm ET HIGHLANDS RANCH, Colo., March 25, 2021 ? Vivos Therapeutics, Inc. (?Vivos? or ?the Company?) (NASDAQ: VVOS), a medical technology company focused on developing and commercial |
|
| March 25, 2021 |
Description of Registered Securities. (1) Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURUSANT TO SECTION 12 FO THE SECURITIES EXCHNAGE ACT OF 1934, AS AMENDED As of December 31, 2020, Vivos Therapeutics, Inc. (the ?Company?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), its common stock, $0.0001 par value per share (?Common Stock?). D |
|
| March 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39796 Vivos Ther |
|
| March 25, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 25, 2021 (March 25, 2021) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction of incorpora |
|
| March 25, 2021 |
EXHIBIT 21.1 Vivos Therapeutics, Inc. Subsidiaries of the Registrant Entity Name Place of Incorporation First Vivos, Inc. Texas BioModeling Solutions, Inc. Oregon Vivos Therapeutics (Canada) Inc. British Columbia Vivos Management and Development, LLC Colorado Vivos Del Mar Management, LLC California |
|
| March 25, 2021 |
Exhibit 10.6 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] identifies that information has been redacted from this exhibit. LICENSING, DISTRIBUTION AND MARKETING AGREEMENT This Licensing, Distribution and Marketing Agreement (this ?Agreement?) is entered into |
|
| February 19, 2021 |
Exhibit 99.1 For Immediate Release Vivos Therapeutics Launches VivoScore Diagnostic Technology for Home Sleep Apnea Testing in Children and Adults VivoScore Opens the Door for More Patients to be Diagnosed and Treated for Sleep Apnea HIGHLANDS RANCH, Colo., February 16, 2021 – Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercial |
|
| February 19, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 19, 2021 (February 12, 2021) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction of inc |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 VIVOS THERAPEUTICS, INC. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 92859E108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
